Phase 1b/2a Multi-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Recurrent Glioblastoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Ibudilast (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors MediciNova
- 19 Dec 2018 Status changed from planning to not yet recruiting.
- 09 May 2018 According to a MediciNova media release, the U.S. Food and Drug Administration (FDA) has accepted the IND for MN-166 in combination with temozolomide for treatment of GBM.
- 08 Mar 2017 New trial record